Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients

Table 2 Amino acid variations in the HCV NS3 protein associated with resistance mutations to HCV NS3 protease inhibitors, compensatory and enhanced replication

NS3 Protease position^a	HCV variation in different genotypes (number of sequenced patients)^b
	1a	1b	2	3	4
	(n = 31)	(n = 39)	(n = 30)	(n = 33)	(n = 23)
36 (R)	V36L ^c (2) ^e	V36	L36	L36	L36
41 (R)	Q41	Q41	Q41	Q41	Q41
43 (R)	F43	F43	F43	F43	F43
54 (R)	T54S (2) ^e	T54	T54	T54	T54
55 (R)	V55A/I (2) ^e	V55F (1) ^e	V55	V55	V55
79 (R)	D79	D79	E79	D79	D79
80 (R)	Q80K/L (3) ^e	Q80L/N (2) ^e	G80	Q80	Q80
109 (R)	R109	R109	R109	R109	R109
138 (R)	S138	S138C (1)^d	S138	S138	S138
155 (R)	R155	R155	R155	R155	R155
156 (R)	A156	A156	A156	A156	A156
158 (R)	V158	V158	V158M (1) ^e	V158	V158
168 (R)	D168	D168	D168	D168Q (33) ^e	D168E (3) ^e
170 (R)	I170	V170I (12)^d	I170	I170V (1)^d	V170
175 (R)	L175	M175L (1) ^e	L175	L175	L175
176 (R)	E176	E176	D176	S176N (4)^d	E176
71 (C)	V71	I71V/L (5) ^e	V71	A71S (1)^d	V71
72 (C)	I72T/F (2) ^e	T72I/A/L (11) ^e	T72	L72F (1)^d	N72C (2)^d
86 (C)	P86	Q86P (6) ^e	P86S (1)^d	P86S (2)^d	P86
88 (C)	P88	P88	P88	P88	P88

^aR, position associated with primary resistance; C, position associated with compensatory mutations; (Lopez, 2008; Flint, 2009; Susser, 2009; Lentz, 2010; Verbimen, 2010; Romano, 2010, Halfon, 2011).
^bReference strains for each genotype: M62321 (1a), D90208 (1b), D50409 (2c), D17763 (3a), and Y11604 (4a).
^cLetter on the left represents the wild type amino acid, on the right, the amino acid substitution. The number of patients with mutant HCV strains is indicated in brackets.
^dPolymorphism with no associated resistance.
^e Amino acid changes conferring resistance are reported in bold.

ISSN: 1743-422X